Editas Medicine, Inc. (EDIT)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 91 | 26 | 20 | 78 | 32 | 41 | 47 | 26 |
| Operating profit | $m | -99 | -82 | ||||||
| Net profit | $m | -116 | -193 | -220 | -153 | -237 | -160 | -74 | -71 |
| EPS reported | $ | -1.80 | -0.75 | ||||||
| Operating cashflow per share | $ | -1.86 | -1.00 | ||||||
| Capex per share | $ | 0.01 | 0.01 | ||||||
| FCF per share | $ | -1.87 | -1.01 | ||||||
| Free cash flow | $m | -166 | -121 | ||||||
| Net debt | $m | -82 | -212 | ||||||
| Book value equity | $m | 27 | 105 | ||||||
| Book value per share | $ | 0.31 | 0.88 | ||||||
| Number of shares | m | 88.75 | 119.29 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | 6.67 | 1.73 | ||||||
| P/S LTM | x | 4.49 | 3.87 | ||||||
| P/FCF LTM | x | -1.10 | -1.51 | ||||||
| EV/EBITDA LTM | x | -0.75 | -1.59 | ||||||
| EV/Sales LTM | x | 2.76 | 5.67 | ||||||
| Earnings Yield LTM | % | -87.98% | -21.98% | ||||||
| FCF Yield | % | -91.16% | -66.26% | ||||||
| Quality | |||||||||
| ROE | % | -586.56% | -196.63% | ||||||
| ROIC | % | -65.65% | -46.81% | ||||||
| Operating margin | % | -2.45% | -1.75% | ||||||
| Gross margin | % | +100.00% | +56.90% | ||||||
| FCF/Sales | % | -409.30% | -256.46% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | +25.39% | +45.46% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | -2.16 | -7.77 | ||||||
| Net Debt/EBITDA | x | 0.47 | 2.37 | ||||||
| EBIT/Net interest | x | -16.10 | 39.05 | ||||||
| Net debt/market cap | % | +35.53% | 0.00% | ||||||
| Net debt/Equity | x | -3.01 | -2.01 | ||||||
| Gross debt/equity | x | 2.81 | 0.15 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. Its lead program is EDIT-401, a one-time therapy designed to reduce LDL cholesterol through the upregulation of the LDL receptor to treat hyperlipidemia. The company also develops therapies to treat Sickle cell disease and transfusion-dependent beta thalassemia; and in vivo gene editing medicines indicated for other cells and tissues. It has a research collaboration with Juno Therapeutics, Inc. to develop alpha-beta T-cell experimental medicines for the treatment of solid and liquid tumors, and autoimmune disease. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. Its lead program is EDIT-401, a one-time therapy designed to reduce LDL cholesterol through the upregulation of the LDL receptor to treat hyperlipidemia. The company also develops therapies to treat Sickle cell disease and transfusion-dependent beta thalassemia; and in vivo gene editing medicines indicated for other cells and tissues. It has a research collaboration with Juno Therapeutics, Inc. to develop alpha-beta T-cell experimental medicines for the treatment of solid and liquid tumors, and autoimmune disease. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free